These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32185680)

  • 21. A Novel Treatment for Neurotrophic Corneal Ulcer Using Topical Cenegermin (OXERVATE™) Containing Recombinant Human Nerve Growth Factor.
    Ahuja AS; Bowden FW; Robben JL
    Cureus; 2020 Nov; 12(11):e11724. PubMed ID: 33391953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers.
    Bremond-Gignac D; Daruich A; Robert MP; Chiambaretta F
    Expert Opin Investig Drugs; 2019 Nov; 28(11):1013-1020. PubMed ID: 31596151
    [No Abstract]   [Full Text] [Related]  

  • 23. Real Life Data on Efficacy and Safety of Topical NGF Eye Drops (Cenegermin).
    Zwingelberg SB; Bachmann BO; Cursiefen C
    Klin Monbl Augenheilkd; 2020 Dec; 237(12):1455-1461. PubMed ID: 33285589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Topical Cenegermin in Management of a Cornea Transplant in a Functionally Monocular Patient with Neurotrophic Keratitis and Facial Nerve Palsy: A Case Report.
    Pocobelli A; Komaiha C; De Carlo L; Pocobelli G; Boni N; Colabelli Gisoldi RAM
    Int Med Case Rep J; 2020; 13():617-621. PubMed ID: 33204181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resolution of a neurotrophic keratopathy associated hypopyon with cenegermin.
    Zambino N; Syed ZA
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101113. PubMed ID: 34307960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.
    Epitropoulos AT; Weiss JL
    Am J Ophthalmol Case Rep; 2022 Sep; 27():101649. PubMed ID: 35938145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.
    García-Delpech S; Udaondo P; Fernández-Santodomingo AS; García-Teillard D
    Case Rep Ophthalmol; 2022; 13(2):663-670. PubMed ID: 36160492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of rh-NGF in the management of neurotrophic keratopathy.
    Roszkowska AM; Spinella R; Calderone A; Sindoni M; Wowra BH; Kozak M; Sajak-Hydzik K; Aliò J
    Front Ophthalmol (Lausanne); 2024; 4():1408587. PubMed ID: 39040985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cenegermin in Pediatric Neurotrophic Keratopathy.
    Pedrotti E; Bonetto J; Cozzini T; Fasolo A; Marchini G
    Cornea; 2019 Nov; 38(11):1450-1452. PubMed ID: 31403527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy.
    Balbuena-Pareja A; Bogen CS; Cox SM; Hamrah P
    Front Neurosci; 2023; 17():1210179. PubMed ID: 37965220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corneal Superficial Plaque Formation After Recombinant Human Nerve Growth Factor Use in a Patient With Neurotrophic Keratopathy and Limbal Stem Cell Deficiency From Mucous Membrane Pemphigoid.
    Surico PL; Kaufman AR; Lin J; Dehghani S; Dana R
    Cornea; 2024 Jul; 43(7):899-902. PubMed ID: 38015976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia.
    Leto MG; Toro ME; Indemini PE; Fruttero C; Denina M; Dalmazzo C; Sannia A; Vaiano AS
    Cornea; 2021 Feb; 40(2):228-231. PubMed ID: 33201057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the Medical Management of Neurotrophic Keratitis.
    Dohlman TH; Singh RB; Dana R
    Semin Ophthalmol; 2021 May; 36(4):335-340. PubMed ID: 33705259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Dry Eye from Laser-Assisted In Situ Keratomileusis With Recombinant Human Nerve Growth Factor (Cenegermin).
    Habibi RN; Lee MD
    Cornea; 2021 Aug; 40(8):1059-1061. PubMed ID: 33214413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Cenegermin in the Presence of Bandage Contact Lenses.
    Cheung AY; Shah AP; Pierson KL; Denny MR; Nordlund ML; Holland EJ
    Cornea; 2022 Jan; 41(1):78-82. PubMed ID: 34870623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Mahon J; Nevitt S; Duarte R; Boland A; Kotas E; Dundar Y; McEntee J; Ahmad S
    Pharmacoecon Open; 2019 Dec; 3(4):453-461. PubMed ID: 31240690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database.
    Li Y; Yang H; Gao Y; He W
    Expert Opin Drug Saf; 2024 Mar; 23(3):385-391. PubMed ID: 37608598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cenegermin for the treatment of dry eye disease.
    Coco G; Piccotti G; Romano V; Ferro Desideri L; Vagge A; Traverso CE; Pellegrini M; Bruscolini A; Marenco M; Giannaccare G
    Drugs Today (Barc); 2023 Mar; 59(3):113-123. PubMed ID: 36847622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotrophic keratopathy.
    Dua HS; Said DG; Messmer EM; Rolando M; Benitez-Del-Castillo JM; Hossain PN; Shortt AJ; Geerling G; Nubile M; Figueiredo FC; Rauz S; Mastropasqua L; Rama P; Baudouin C
    Prog Retin Eye Res; 2018 Sep; 66():107-131. PubMed ID: 29698813
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.